MO-VERNE-GLOBAL
15.11.2021 14:02:11 CET | Business Wire | Press release
Verne Global , provider of sustainable data center solutions for high intensity computing, recently acquired by Digital 9 Infrastructure plc (D9), today announced that it is expanding its 40-acre data center campus by a further 10MW of constructed power capacity. The expansion is backed by D9, the investment trust that focuses on sustainable digital infrastructure assets, which will fund the $50m development of new enterprise-class data center space.
Ideally located with access to abundant, low-cost renewable energy and a highly reliable national electrical grid, the Icelandic data center company continues to attract a range of enterprise customers as demand for high intensity compute sees sustained growth across industries. As more companies look to decarbonize their digital infrastructure by powering intensive applications such as artificial intelligence, mathematical modelling and predictive analytics with cleaner, greener energy, Verne Global is expanding now to meet contracted demand. The data center company’s best-in-class onsite technical and operations team will continue to use its specialized expertise to work around the clock to support and optimize the high density environments and workloads it houses.
“We’re seeing sector after sector looking to move into high performance analytics environments and it’s exciting to scale our campus again alongside new and existing customers to meet that need,” said Dominic Ward, CEO at Verne Global. “It’s great to also take this first step into the future as part of the D9 Infrastructure platform, and we are all eagerly looking forward to what comes next.”
“We are proud to support Verne Global and play a part in bringing its vision for the future into reality,” said Thor Johnsen, Head of Digital Infrastructure at Triple Point, D9’s investment manager. “Powered by Iceland’s abundant green power, Verne Global’s expanded data center will be even better placed to provide resilient digital infrastructure that offers a true reduction in carbon emissions for its customers alongside long-term economic and sustainable stability.”
As part of this expansion, Verne Global is partnering with Integra Mission Critical , the modular data center solutions provider, to optimize its delivery of sustainable high intensity compute at scale while fitting out the new data center space. Utilizing Integra’s solution-driven engineering expertise to implement modular data center infrastructure will allow Verne Global to increase sustainability measures in line with its core mission, while promoting scalability and safety, and decreasing cost.
“Verne Global’s facility has been built from the ground up for highly specialist data center services that are sustainable, scalable and bespoke,” said John Kolar, Principal at Integra Mission Critical. “These mutual principles make our companies a natural fit and we’re so excited to be teaming up and putting our decades of experience in solution-driven engineering to good use to provide a quality turnkey infrastructure solution for the new space.”
SC21 delegates can visit Verne Global at the Data Centers by Iceland stand (#1819) at SC21 in St Louis, MO, 15-19 November, 2021.
About Verne Global
Verne Global delivers data center solutions for high intensity computing, engineered for optimal high performance compute and built upon 100% renewable energy. Our clean grid and stable climate cuts costs and energy usage, and our expert team provides on-site, around-the-clock support to maximize performance and flexibility for customer workloads.
Founded in 2012, our Icelandic data center campus powers some of the world’s most innovative and demanding industries, including financial services, earth sciences, life sciences, engineering, scientific research and AI.
About Integra Mission Critical
Integra Mission Critical delivers modular mechanical, electrical and plumbing (MEP) solutions for the mission critical sector. With in-house manufacturing facilities throughout the United States, Europe, and Asia, Integra Mission Critical has a global reach with a local focus. Our solutions-driven engineering enables us to meet each customer’s specific needs across the globe, whether that be specialized cooling for a specific climate, or sustainable solutions for backup power generation.
Integra Mission Critical leverages innovative designs and an integrated approach and combines them with our relentless passion to mitigate risk, compress the schedule, reduce costs, and close the gap between capex and revenue generation.
Founded in 2014, with a focus on cooling solutions, Integra Mission Critical has since expanded into electrical solutions (2017), ranging from electrical skids to modular electrical rooms, to complete modular data centers. Our North America headquarters are in Dallas, Texas with our European headquarters in London, England.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom